Visual Abstract: Combination Casirivimab, Imdevimab, Development of Symptomatic COVID-19 in SARS-CoV-2 Infection

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JANUARY 14, 2022

Media advisory: The full article and editorial are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.24939?guestAccessKey=3b962c7d-3338-45b6-ac51-865ff698ea4d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=011422

 

Visual Abstract

 

Authors: Meagan P. O’Brien, M.D., of Regeneron Pharmaceuticals Inc., in Tarrytown, New York, is the corresponding author.

(doi:10.1001/jama.2021.24939)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.